REJECTED: FDA snub of sugammadex another setback for Merck
This article was originally published in Scrip
The fact Merck's shares dipped only slightly – less than 1% – on 23 September was evidence investors likely had prepared themselves in advance for the company's almost predictable revelation the US FDA had, for the second time, rejected the pharma's new drug application (NDA) for sugammadex sodium injection to reverse and speed the recovery from the neuromuscular blockade effects of the muscle relaxants rocuronium and vecuronium, which are used during some types of surgery to make it easier for the surgeon to do the procedure.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.